



Universiteit  
Leiden  
The Netherlands

## **Cutaneous B-cell lymphoma : classification, prognostic factors and management recommendations**

Senff, N.J.

### **Citation**

Senff, N. J. (2009, February 12). *Cutaneous B-cell lymphoma : classification, prognostic factors and management recommendations*. Retrieved from <https://hdl.handle.net/1887/13473>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/13473>

**Note:** To cite this publication please use the final published version (if applicable).

## Chapter 3.

### **Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type**

*Journal of Investigative Dermatology, in press*

Nancy J. Senff<sup>1\*</sup>, Willem H. Zoutman<sup>1\*</sup>, Maarten H. Vermeer<sup>1</sup>, Chalid Assaf<sup>2</sup>, Emilio Berti<sup>3</sup>, Lorenzo Cerroni<sup>4</sup>, Blanca Espinet<sup>5</sup>, Ricardo Fernandez de Misa Cabrera<sup>6</sup>, Marie-Louise Geerts<sup>7</sup>, Werner Kempf<sup>8</sup>, Tracey J. Mitchell<sup>9</sup>, Marco Paulli<sup>10</sup>, Tony Petrella<sup>11</sup>, Nicola Pimpinelli<sup>12</sup>, Marco Santucci<sup>13</sup>, Sean J. Whittaker<sup>9</sup>, Rein Willemze<sup>1</sup> and Cornelis P. Tensen<sup>1</sup>. \* Both authors contributed equally

<sup>1</sup>Dept. of Dermatology, Leiden University Medical Center, Leiden, the Netherlands; <sup>2</sup>Dept. of Dermatology, Skin Cancer Center, Charité-Universitätsmedizin, Berlin, Germany; <sup>3</sup>Dept. of Dermatology, University of Milan-Biococca and Fondazione Ospedale Policlinico, Regina Elena and Mangiagalli, Istituti di ricovero e cura a carattere scientifico, Milan, Italy; <sup>4</sup>Dept. of Dermatology, University of Graz, Graz, Austria; <sup>5</sup>Servei de Patologia (Laboratori de Citogenètica i Biologia Molecular), Hospital del Mar, Barcelona, Spain on behalf of "Xarxa de Limfomes Cutanis de Catalunya"; <sup>6</sup>Dept. of Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain; <sup>7</sup>Dept. of Dermatology, University Hospital Gent, Gent, Belgium; <sup>8</sup>Dept. of Dermatology, University Hospital Zürich, Zürich, Switzerland; <sup>9</sup>Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, United Kingdom; <sup>10</sup>Dept. of Pathology, University of Pavia, Pavia, Italy; <sup>11</sup>Center of Pathology and Dept. of Pathology of the University Hospital Dijon, Dijon, France; <sup>12</sup>Dept. of Dermatological Sciences, University of Florence Medical School, Florence, Italy <sup>13</sup>Dept. of Human Pathology and Oncology, University of Florence, Florence, Italy.

**Abstract**

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL, LT) is the most aggressive type of primary cutaneous B-cell lymphoma. In a recent study on 12 patients it was found that inactivation of CDKN2A by either deletion of 9p21.3 or promoter hypermethylation is correlated with a worse prognosis.

In the present EORTC multi-centre study, skin biopsies of 64 PCLBCL, LT patients were analyzed by Multiplex Ligation-dependent Probe Amplification to validate these previous results and to fine-map the losses in this region. Although no minimal common region of loss could be identified, most homozygous loss was observed in the CDKN2A gene (43/64; 67%) encoding p16 and p14ARF. Promoter hypermethylation of p16 and p14/ARF was found in six and zero cases respectively. Survival was markedly different between patients with versus without aberrations in the CDKN2A gene (5-year disease-specific survival 43% versus 70%;  $p = 0.06$ ). In conclusion, our results confirm that deletion of chromosome 9p21.3 is found in a considerable proportion of PCLBCL, LT patients and that inactivation of the CDKN2A gene is associated with an unfavourable prognosis. In most patients the deletion involves a large area of at least several kilobasepairs instead of a small minimal common region.

## Introduction

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL, LT) is the most aggressive type of primary cutaneous B-cell lymphoma (CBCL). It is generally characterized by rapidly growing tumours that present on the leg(s), but in a minority of patients skin lesions can also arise at other sites. Histologically it is defined as a tumour with a predominance or confluent sheets of large, atypical B-cells (resembling centroblasts and immunoblasts), which generally express Bcl-2 and MUM-1. The disease has an intermediate prognosis with a 5-year survival rate of only 50%.<sup>1</sup> Since it is recognized that this disease represents a distinct type of CBCL, it will be included as a separate entity in the forthcoming WHO 2008 classification.

In a recent study by our group, using array-based comparative genomic hybridization (aCGH), it was found that inactivation of the CDKN2A region, encoding for the tumour suppressor genes p16 and p14ARF, by either deletion of chromosome 9p21.3 or promoter hypermethylation, is associated with a worse prognosis. However, these results were based on only 12 cases.<sup>2</sup>

Multiplex Ligation-dependent Probe Amplification (MLPA) has recently been described as a new method for relative quantification of multiple different DNA sequences in a single reaction, requiring only small amounts of DNA.<sup>3</sup> Moreover, the application of this technique on DNA isolated from formalin-fixed, paraffin-embedded (FFPE) material has previously been reported to be reliable and less sensitive to DNA degradation.<sup>4-6</sup> Targeted MLPA probe panels are commercially available including a set of probes targeting the chromosomal region of 9p21 containing several known genes (CDKN2A, coding for p16 and p14ARF, CDKN2B, coding for p15 and MTAP).

In the present study, MLPA was used to confirm that inactivation of CDKN2A is an unfavourable prognostic marker in a large patient group and to further fine-map the 9p21.3 region in order to determine a possible minimal common region.

## Results


### *Testing the reliability of the MLPA technique*

We first investigated whether results generated by MLPA were in accordance with our previous aCGH results.<sup>2</sup> In addition, we aimed to obtain more information on the precise location of deletions as the MLPA technique has a much higher spatial resolution than the aCGH technique applied previously (see Figure 1).<sup>2</sup> To that end, we subjected available isolated DNA from 12 patients (9 PCLBCL, LT and 3 primary cutaneous follicle centre lymphomas (PCFCL) previously investigated by aCGH to MLPA. We were indeed able to confirm chromosomal aberrations in 9p21.3 as detected by aCGH in all patients, with homozygous loss in four of 12 patients and hemizygous loss in two of 12 patients using MLPA (See Figure 2). Moreover, in three of the six patients that did not show loss in the aCGH analysis (three PCLBCL, LT and three PCFCL), MLPA allowed detection of hemizygous loss (and in one patient even homozygous loss) of individual probes within the

complete set (two PCLBCL, LT and one PCFCL) (see Figure 2). This demonstrates the higher sensitivity of the MLPA technique as compared to the aCGH platform previously used. However, we could not detect a minimal common region of deletion within the CDKN2A gene region.

Since a considerable part of our samples was derived from FFPE material, it was felt important to test the claim that MLPA can be applied as reliably to DNA isolated from FFPE material as to DNA isolated from frozen material.<sup>6</sup> To accomplish this, we analysed DNA from fresh-frozen samples and FFPE material taken simultaneously from the same tumour. This was done in two patients from whom at three different time points biopsy material was collected (primary tumour, first skin relapse and second skin relapse). We observed full concordance of the results as depicted for one patient in Figure 3, thereby demonstrating the applicability of this technique on partly degraded DNA. In addition, it was noted that the genetic lesions in the 9p21.3 region showed a stable pattern over time and did not alter with disease progression and treatment.

**Figure 1. Schematical representation of 9p21.3 showing the spatial resolution of different techniques.**



MLPA can be used to fine-map the chromosomal aberrations as found by aCGH (BAC clone RP11-149I2 corresponding to 21899259-22000413 (according to Ensembl) on chr. 9) and FISH (e.g. LSI p16 probe from Vysis which, according to the manufacturer, at least includes the region from 21792942 (D9S1749) - to 21995210 (D9S1752) on chromosome 9). Exact genomic positions of the MLPA probes can be requested at MRC Holland (info@mlpa.com).

Figure 2. Array CGH vs. MLPA results for PCLBCL, LT (n = 9) and PCFCL patients (n = 3).

MLPA results	PCLBCL, LT (n = 9)									PCFCL (n = 3)		
	# 1	# 2	# 3	# 4	# 5	# 6	# 7	# 8	# 9	# 10	# 11	# 12
p15, promoter+exon 1	0.17	0.13	0.41	0.5	1.02	0.99	1.03	0.86	1.13	0.93	1.09	0.81
p15, end exon 1	0.13	0.13	0.41	0.45	1.04	0.88	1.05	0.98	1.02	0.99	1.09	0.95
ltboi, p15/p14ARF	0.17	0.14	0.23	0.42	0.74	0.65	1.01	0.54	0.24	0.95	1.03	0.93
p14ARF, promoter	0.18	0.09	0.5	0.42	1.14	0.91	1.09	0.77	0.67	0.99	1.4	1.17
p14ARF, promoter near TSS	0.13	0.11	0.42	0.52	1.18	0.97	1.07	0.83	1.33	0.97	1.23	0.99
p14ARF, exon 1	0.16	0.08	0.25	0.32	0.93	0.73	0.9	0.79	0.63	1.04	1.17	1.01
ltboi, p14ARF/p16	0.13	0.09	0.28	0.43	0.4	0.61	0.92	0.62	1	0.91	0.93	0.86
ltboi, p14ARF/p16	0.12	0.06	0.37	0.42	0.41	0.74	0.86	0.67	1.05	0.73	0.81	0.67
p15, exon 1	0.19	0.09	0.57	0.48	0.59	1.02	1.32	0.82	1.15	1.19	2	1.45
p15, exon 1	0.17	0.07	0.5	0.41	0.57	0.91	1.13	0.82	1.35	1.04	1.29	0.97
p15, exon 2	0.13	0.09	0.27	0.46	0.45	0.76	0.99	0.56	1.36	1.09	0.95	0.68
p15, exon 3	0.13	0.07	0.43	0.38	0.47	0.8	0.92	0.77	1.13	0.97	1.03	0.93
MTAP, End	0.13	0.07	0.31	0.34	0.81	0.69	0.85	0.89	0.78	0.95	1.01	0.95
MTAP	0.19	0.1	0.4	0.38	0.82	0.76	1.06	0.97	0.7	1.02	1.13	1.02
MTAP, Start	0.19	0.09	1.16	1.09	1	1.08	1.03	1.09	0.66	1.21	1.41	1.05
aCGH results (Log2 ratio)	-0.92	-0.94	-0.48	-0.50	-0.26	-0.24	-0.05	0.15	-0.06	0.04	-0.02	-0.07
SD	0.12	0	0.05	0.04	0.05	0.03	0.03	0.03	0.03	0.07	0.03	0.01
Follow-up	D+ 12	D+ 26	D+ 21	D+ 11	A- 85	A- 60	A- 82	D+ 54	D- 18	A- 264	A- 62	A- 60

D+ = died of lymphoma, D- = died of other cause, A- = alive in complete remission. Black = homozygous loss, grey = hemizygous loss, white = no loss.

#### Allelic loss at the 9p21.3 locus


Having confirmed that MLPA can reliably detect genetic lesions in frozen as well as in FFPE material, we subjected the whole study group to MLPA. In total, tumour biopsies from 64 patients with a diagnosis of PCLBCL, LT were included in the final study group. This included the nine patients previously analyzed by aCGH and in addition 55 new patients. The overall MLPA results for these patients are depicted in Figure 4. It was found that 45 patients (70%) showed homozygous loss of one or multiple probes within the 9p21.3 region. Hemizygous loss was found in 14 patients and five patients did not show any detectable loss in this region.

Most chromosomal aberrations were localized in the CDKN2A gene. Homozygous loss within this region was found in 43/64 cases (67%). Homozygous losses in the coding regions for p16 (exon 1 $\alpha$ , 2 and 3) and p14ARF (exon 1 $\beta$  and 2), as well as both promoter regions, were found in 40/64 (63%) and 37/64 (58%) cases respectively. Specific probes, most often lost were located in exon 1 $\alpha$  coding for p16 and exon 2 coding for both p16 and p14ARF (both probes were lost in 31/64 cases; 48%). In most patients however, the deletion covered a large part of chromosome 9p21.3 instead of a smaller minimal common region (see Figure 4).

*Analysis of p16 and p14ARF promoter methylation status*


From 20/21 patients without homozygous loss in CDKN2A, sufficient DNA was available to determine the promoter methylation status of p16 and p14ARF. In none of the samples methylation of the p14ARF promoter was found. However, methylation of the p16 promoter was detected in 6/20 samples. Five of these samples showed hemizygous loss within the p16 coding and promoter region in MLPA analysis and one sample had no loss within this region.

**Figure 3. MLPA results for DNA from fresh frozen (black bars) versus FFPE material (grey bars) from one patient.**



Skin biopsies obtained at diagnosis (A), at first skin relapse after 32 months (B) and at second skin relapse after 39 months (C). FR: flanking region

Figure 4. Total MLPA results for 64 PCLBCL, LT patients.




Black = homozygous loss (ratio < 0.4), grey = hemizygous loss (ratio between 0.4 and 0.7), white = no loss (ratio > 0.7). FR: flanking region



### Correlation with survival


Survival analysis revealed a clear correlation between homozygous loss in chromosome 9p21.3 and reduced survival. Patients without homozygous loss in this region had an actuarial 5-year disease-specific survival (DSS) of 68%, while patients with loss of at least one probe in this region had a 5-year DSS of 39% ( $p = 0.06$ ). Although statistically not significant, these results are in line with the findings described by Dijkman et al.<sup>9</sup> Since most loss occurred in the CDKN2A region, we also performed survival analysis for losses specific to this region and in addition also for loss in areas coding specifically for p14ARF and p16 separately. Loss in the CDKN2A region was most strongly correlated with prognosis. Five-year DSS for patients with or without loss in this region was 38% versus 69% ( $p = 0.03$ ) (See Figure 5). Differences in 5-year DSS between patients with or without losses in the regions coding p14ARF or p16 were not or borderline significant, respectively. Finally, we tested whether inclusion of the methylation data affected the survival analysis. In the complete study group a total of 48 patients can be considered to have an inactivated CDKN2A gene (43 patients with homozygous loss in the CDKN2A gene and 5 patients with a methylated p16 promoter combined with hemizygous loss in CDKN2A). Five-year DSS for patients with and those without inactivation of CDKN2A are 70% and 43% respectively ( $p = 0,059$ )(See Figure 6).

**Figure 5. Disease-specific survival of 64 PCLBCL, LT patients according to chromosomal aberrations within CDKN2A.**



Solid line: patients with homozygous loss of one or multiple probes in CDKN2A ( $n = 43$ ), dashed line: patients with no or hemizygous loss in CDKN2A ( $n = 21$ ). Error bars indicate Standard Error.

Figure 6. Disease-specific survival of 63 PCLBCL, LT patients according to CDKN2A status.



Solid line: patients with inactivation of CDKN2A (n = 48), dashed line: patients without inactivation of CDKN2A (n = 15). In one patient no DNA was available for determining methylation status, this patient is not included in this analysis. Error bars indicate Standard Error.

### Discussion

In this study we aimed to confirm recently reported data describing that loss of 9p21.3 and more specifically, inactivation of CDKN2A is commonly found and associated with inferior prognosis in PCLBCL, LT.<sup>2</sup> By using MLPA we were able to confirm loss of 9p21.3, including the CDKN2A gene, on a large group of patients with PCLBCL, LT. We observed full concordance with the results as obtained by aCGH, and, in addition, detected small areas of loss in three patients. So comparison between aCGH and MLPA confirms the higher sensitivity of the latter technique and its ability to fine-map larger areas of loss as found by genome-wide analyses such as aCGH using BAC clones as in the previous study. It was found that in most patients the deletion covers a substantial part (up to several tens of thousands of basepairs) of this chromosomal region. Although no minimal common region of loss could be detected, most chromosomal aberrations converged on the CDKN2A gene. An additional advantage of the MLPA technique is that it can be applied reliably on FFPE material of CBCL patients. Comparison between DNA derived from fresh-frozen and FFPE sections, obtained from the same tumour in two patients, showed identical results. Moreover, comparison of skin biopsy specimens obtained from consecutive tumours in these two patients, demonstrated identical chromosomal aberrations, indicating that these losses can display a stable pattern over time.

Loss or inactivation of the CDKN2A gene either by deletion or promoter hypermethylation has been extensively reported in haematological malignancies, including B-cell non-Hodgkin lymphomas.<sup>7-10</sup> CDKN2A codes for p16 and p14ARF, both of which are tumour suppressor genes and are negative regulators of cell cycle progression. In our study group, inactivation of CDKN2A was mostly due to (homozygous) deletion. Promoter hypermethylation of p16 was found in a minority of cases, which is in accordance with the results of previous studies in CBCL.<sup>11;12</sup> Promoter hypermethylation of p14 was never detected.

Besides confirming the loss in this chromosomal region we further wanted to validate the prognostic significance of the findings as reported previously. Although less striking than the results reported by Dijkman et al<sup>2</sup>, loss or inactivation of CDKN2A, was still associated with reduced survival (See Figures 5 and 6), which is also consistent with previous reports of others.<sup>11-13</sup> Even though the results described herein show a clear, and borderline significant, correlation with reduced survival, loss of CDKN2A can not be used as the sole tool to optimize management in individual patients.

In our study group there are several patients with deletions in 9p21.3, that have a favourable clinical course thus far. More importantly, five of 21 patients without inactivation of CDKN2A died of lymphoma 6-54 months (median 27 months) after diagnosis. Especially this latter group runs the risk of being undertreated when management would be solely based on CDKN2A status.

In conclusion, in a large part of PCLBCL, LT patients chromosomal loss is seen in 9p21.3. In most patients these losses are concentrated on the CDKN2A gene coding for p16 and p14ARF. Inactivation of this gene is caused by homozygous deletion or, less commonly, by promoter hypermethylation and is associated with a worse prognosis. However, caution is warranted before these results are incorporated into clinical decision making.

## **Material and Methods**

### *Sample collection*

Cases were collected from centres collaborating in the EORTC Cutaneous Lymphoma Group. Tumour DNA from pre-treatment skin biopsies of 80 patients were initially submitted for the study. Patients with incomplete staging investigations (minimum requirements being routine laboratory screening, CT scans of chest and abdomen and bone marrow biopsy) or follow-up of less than 12 months (unless caused by death due to lymphoma) were excluded from further analysis (n = 6). In addition, of all submitted cases H&E sections were reviewed for morphological reference and estimation of percentage tumour- and admixed reactive cells. In case of doubt about the percentage of tumour cells, we reviewed stainings for CD3 and CD20. If these were not available, the case was excluded. Combined with information on the expression of Bcl-2, MUM-1 and FOXP1, a diagnosis of PCLBCL, LT was confirmed or discarded. Cases in which a diagnosis of PCLBCL, LT could not be confirmed and cases with more than 30% admixed reactive T-

cells were excluded (n = 5). Finally, five cases could not be analyzed due to poor quality DNA. The final study group consisted of 64 patients with a diagnosis of PCLBCL, LT. The study group contained 25 males and 39 females (male-female ratio: 0,6), with a median age at diagnosis of 78 years (range 47-92 years) and a median duration of follow-up of 34 months (range 2-158 months). Clinical characteristics and treatment data are presented in Table 1. In addition, 3 patients with a diagnosis of primary cutaneous follicle centre lymphoma (PCFCL) were included in the experiment validating the MLPA technique. Twelve of the above described patients (9 PCLBCL, LT and 3 PCFCL) were formerly analyzed with aCGH.<sup>2</sup> Genomic DNA was extracted from either fresh frozen material, or FFPE sections, using local protocols.

**Table 1. Clinical and treatment characteristics of 64 patients with PCLBCL, LT.**

<b>Total number of patients</b>	<b>64</b>
<b>Age, years</b>	
Median (range)	78 (47-92)
<b>Sex</b>	
Male	25
Female	39
male:female ratio	0.6
<b>Site of skin lesions (%)</b>	
Head/ neck	2 (3%)
Trunk	7 (11%)
Arm(s)	2 (3%)
Leg(s)	59 (92%)
<b>Extent of skin lesions (%)</b>	
Solitary	26 (41%)
Regional	30 (47%)
Multifocal	8 (13%)
<b>Treatment (%)</b>	
Radiotherapy	32 (50%)
Chemotherapy	15 (23%)
Chemotherapy and radiotherapy	9 (14%)
Surgery	3 (5%)
Surgery and radiotherapy	2 (3%)
Rituximab	1 (2%)
Other	2 (3%)
<b>Result of treatment (%)</b>	
Complete remission	54 (84%)
Partial remission	6 (9%)
No response	3 (5%)
Progressive disease	1 (2%)
<b>Status at last follow-up (%)</b>	
Alive and well	23 (36%)
Alive with disease	6 (9%)
Died of lymphoma	30 (47%)
Died of other cause	5 (8%)

#### *Fine-mapping chromosomal loss at 9p21.3 using MLPA*

A commercially available MLPA Kit (SALSA MLPA Kit P024B; MRC-Holland, Amsterdam, the Netherlands) targeting the 9p21 region was used according to the manufacturer's protocol. The P024B kit contains 23 probes of which 9 probes are specific for the CDKN2A region, 3 probes for the CDKN2B region and 3 probes for the MTAP gene, while 8 probes hybridize to regions flanking these genes. For the experiments we used 60-80 ng of genomic DNA and normal control DNA (a DNA mix of 15 healthy donors) was always included in the same reaction. The principles of the MLPA technique are concisely described by Vorstman et al.<sup>14</sup>, while detailed methodology can be found in the paper by Schouten et al.<sup>3</sup>

Briefly, genomic DNA diluted in 5 µl of Tris-EDTA 10mM, was denatured at 95°C for 5 min, mixed with the probe set and the MLPA buffer, and incubated for 16 hr at 60°C. After probe hybridisation, products were ligated for 15 min at 54°C. The ligase enzyme was then inactivated by incubation for 5 min at 98°C. The ligation products were subsequently amplified by PCR using universal FAM-labelled primers. All these reactions were carried out in a PTC-200 Thermal cycler with heated lid (MJ Research, Waltham, Massachusetts). The resulting products were separated according to size on an ABI Prism 3730 DNA analyzer (Applied Biosystems, Nieuwerkerk aan den IJssel, the Netherlands) by the inclusion of GeneScan ROX 500 as internal size standard (Applied Biosystems). Resulting fragment analysis chromatograms were sized to standard fragment lengths by GeneMapper v3.7 (Applied Biosystems).

#### *Promoter hypermethylation analysis*

Since promoter hypermethylation can be involved in gene inactivation, we also evaluated the methylation status of the CpG islands, located in the promoter regions of p16 and p14ARF, in patients without homozygous loss of (parts of) the CDKN2A gene. Promoter methylation status was determined by performing melting curve analysis of bisulfite converted and PCR amplified tumour DNA, as described previously.<sup>15</sup> Tumour DNA was modified with sodium bisulfite by using the EZ Methylation Kit (Zymo Research Corporation, Orange, CA). PCR primers were designed to anneal to bisulfite-converted DNA as template which amplified a region of the p16 and p14ARF gene promoter CpG islands (see Table 2). PCR amplification of bisulfite-treated DNA and subsequent melting curve analysis in the presence of SYBRGreen (MyiQ Real-time PCR Detection System; Bio-Rad Laboratories BV, Veenendaal, the Netherlands) allowed detection of methylation present in the sample DNA, by generating a peak with a higher melting temperature as compared to unmethylated DNA. Ratios for methylated versus unmethylated DNA in each sample were determined by dividing the total area under the melting temperature curve(s) by the area under the methylation specific peak. All samples showing a ratio above 0.3 were considered to contain methylated tumour DNA.

**Table 2. PCR primer sequences, designed to anneal to bisulfite-converted DNA as template, for p16 and p14ARF gene promoter CpG islands.**

Gene	Primer sequence (5' - 3')	CpGs in Amplicon	Position of Amplicon Relative to Transcription Start Site	Amplicon Size (bp)
p16	GATTTAATTGGTAGTTAGGAAGGTTGT	10	-299, -159	140
	GGTTGGGAGTAGGGAGGTCG			
p14ARF	GAGGGGAGTTAGGAATAAATAAGG	10	-413, -268	145
	CTAAAACGCAACTCCAACAACACT			

#### *Data analysis and statistical methods*

Analysis of MLPA results was carried out upon the transfer of GeneMapper results to Coffalyser software, a data analysis tool which was designed by MRC-Holland for normalization of MLPA fragment data files. With this programme, DNA copy number ratios of test samples can be computed, by comparison and normalization to a control sample (for full description see: <http://www.mlpa.com/coffalyser/>). Since sample DNA is compared against a normal control sample, a ratio of 0.5 would ideally indicate hemizygous loss and zero would indicate homozygous loss. However, considering the fact that our samples contained a maximum of 30% admixed reactive cells, ratios between 0.4 and 0.7 were considered as hemizygous loss, while ratios below 0.4 were considered as homozygous loss.

For analysis of clinical data and performing survival analyses, SPSS 14.0 (SPSS Inc., Chicago, IL, U.S.A.) was used. Disease-specific survival (DSS) was calculated from the date of diagnosis until death from lymphoma (including therapy-related death) or last follow-up without event. Survival curves were estimated using the method of Kaplan and Meier and statistical comparison between curves was done by log-rank testing.

#### **Conflict of interest**

The authors state no conflict of interest.

#### **Acknowledgements**

The authors wish to thank Ronald van Eijk and Remco van Doorn for helpful discussions, Pieter van der Velden for providing the p16 PCR primers and Ramon M<sup>a</sup> Pujol and Fernando Gallardo from Hospital del Mar de Barcelona, Octavio Servitje from Hospital Universitari de Bellvitge, Teresa Estrach from Hospital Clínic de Barcelona and M<sup>a</sup> Pilar García-Muret from Hospital de la Santa Creu i Sant Pau de Barcelona, Spain for providing samples proceeding from the "Xarxa de Limfomes Cutanis de Catalunya" included in the study. This study was supported by a grant from the Dutch Cancer Society (UL 2006-3705).

## References

1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. *Blood* 2005;105:3768-3785.
2. Dijkman R, Tensen CP, Jordanova ES et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. *J.Clin.Oncol.* 2006;24:296-305.
3. Schouten JP, McElgunn CJ, Waaijer R et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. *Nucleic Acids Res.* 2002;30:e57.
4. Natte R, van Eijk R, Eilers P et al. Multiplex ligation-dependent probe amplification for the detection of 1p and 19q chromosomal loss in oligodendroglial tumors. *Brain Pathol.* 2005;15:192-197.
5. Takata M, Suzuki T, Ansai S et al. Genome profiling of melanocytic tumors using multiplex ligation-dependent probe amplification (MLPA): Its usefulness as an adjunctive diagnostic tool for melanocytic tumors. *J.Dermatol.Sci.* 2005;40:51-57.
6. van Dijk MC, Rombout PD, Boots-Sprenger SH et al. Multiplex ligation-dependent probe amplification for the detection of chromosomal gains and losses in formalin-fixed tissue. *Diagn.Mol.Pathol.* 2005;14:9-16.
7. Baur AS, Shaw P, Burri N et al. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. *Blood* 1999;94:1773-1781.
8. Dreyling MH, Roulston D, Bohlander SK, Vardiman J, Olopade OI. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma. *Genes Chromosomes.Cancer* 1998;22:72-78.
9. Raschke S, Balz V, Efferth T, Schulz WA, Florl AR. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines. *Genes Chromosomes.Cancer* 2005;42:58-67.
10. Sanchez-Beato M, Saez AI, Navas IC et al. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. *Am.J.Pathol.* 2001;159:205-213.
11. Belaud-Rotureau MA, Marietta V, Vergier B et al. Inactivation of p16INK4a/CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas. *Virchows Arch.* 2008;452:607-620.

12. Gronbaek K, Moller PH, Nedergaard T et al. Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. *Br.J.Dermatol.* 2000;142:913-923.
13. Child FJ, Scarisbrick JJ, Calonje E et al. Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma. *J.Invest Dermatol.* 2002;118:941-948.
14. Vorstman JA, Jalali GR, Rappaport EF et al. MLPA: a rapid, reliable, and sensitive method for detection and analysis of abnormalities of 22q. *Hum.Mutat.* 2006
15. Worm J, Aggerholm A, Guldberg P. In-tube DNA methylation profiling by fluorescence melting curve analysis. *Clin.Chem.* 2001;47:1183-1189.



